undefined undefined Novavax ( NASDAQ: NVAX ) has submitted an application to the U.S. FDA to amend an Emergency Use Authorization to cover its new JN.
1 vaccine. The agency, as well as the European Medicines Agency and WHO, have recommended COVID shots that target the JN.1 lineage for the fall.
The company noted that its vaccine is also effective against variant strains, such as KP.2 and KP.3.
Novavax intends to have the new vaccines available for distribution by the middle of August. More on Novavax Novavax: Sanofi Partnership Revitalizes My Magnum Opus FDA recommends KP.2 strain be used in updated COVID-19 shots FDA selects JN.
1 variant for next COVID vaccine campaign Novavax, Inc. (NVAX) Jefferies 2024 Global Healthcare Conference (Transcript) Novavax, Inc. (NVAX) Q1 2024 Earnings Call Transcript.
